Skip to Content
Merck
CN
  • Clinical, pathologic, and mutational spectrum of dystroglycanopathy caused by LARGE mutations.

Clinical, pathologic, and mutational spectrum of dystroglycanopathy caused by LARGE mutations.

Journal of neuropathology and experimental neurology (2014-04-09)
Katherine G Meilleur, Kristen Zukosky, Livija Medne, Pierre Fequiere, Nina Powell-Hamilton, Thomas L Winder, Abdulaziz Alsaman, Ayman W El-Hattab, Jahannaz Dastgir, Ying Hu, Sandra Donkervoort, Jeffrey A Golden, Ralph Eagle, Richard Finkel, Mena Scavina, Ian C Hood, Lucy B Rorke-Adams, Carsten G Bönnemann
ABSTRACT

Dystroglycanopathies are a subtype of congenital muscular dystrophy of varying severity that can affect the brain and eyes, ranging from Walker-Warburg syndrome with severe brain malformation to milder congenital muscular dystrophy presentations with affected or normal cognition and later onset. Mutations in dystroglycanopathy genes affect a specific glycoepitope on α-dystroglycan; of the 14 genes implicated to date, LARGE encodes the glycosyltransferase that adds the final xylose and glucuronic acid, allowing α-dystroglycan to bind ligands, including laminin 211 and neurexin. Only 11 patients with LARGE mutations have been reported. We report the clinical, neuroimaging, and genetic features of 4 additional patients. We confirm that gross deletions and rearrangements are important mutational mechanisms for LARGE. The brain abnormalities overshadowed the initially mild muscle phenotype in all 4 patients. We present the first comprehensive postnatal neuropathology of the brain, spinal cord, and eyes of a patient with a homozygous LARGE mutation at Cys443. In this patient, polymicrogyria was the predominant cortical malformation; densely festooned polymicrogyria were overlaid by a continuous agyric surface. In view of the severity of these abnormalities, Cys443 may be a functionally important residue in the LARGE protein, whereas the mutation p.Glu509Lys of Patient 1 in this study may confer a milder phenotype. Overall, these results expand the clinical and genetic spectrum of dystroglycanopathy.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-Reelin Antibody, a.a. 164-189 mreelin, clone 142, clone 142, Chemicon®, from mouse
Sigma-Aldrich
Phosphorylase b from rabbit muscle, lyophilized powder, ≥20 units/mg protein, 2× crystallization
Sigma-Aldrich
Phosphorylase b from rabbit muscle, For use as a marker in SDS-PAGE